Semaglutide is a modified GLP-1-receptor agonist peptide used in incretin-signaling and metabolic laboratory research. The original overview of this page asks three questions: GLP-1-receptor agonism, sequence modifications and extended exposure, and identity, purity, content, and aggregation review for the lot on the bench.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
GLP-1-analogue identity and sequence modifications
Lau and colleagues described semaglutide as a once-weekly glucagon-like peptide-1 (GLP-1) analogue designed to increase albumin affinity and to remain stable against metabolic degradation. Relative to human GLP-1, they reported two amino-acid substitutions, Aib8 and Arg34, and derivatization at lysine 26; the fatty-acid moiety and linking chemistry were the features they identified as securing albumin affinity, receptor potency, and prolonged exposure (Lau et al., 2015). That identity places semaglutide in the selective GLP-1-receptor family. It is not tirzepatide, a dual GIP/GLP-1 agonist, and it is not retatrutide, a triple glucagon/GIP/GLP-1 agonist. See Tirzepatide: Dual GIP/GLP-1 Agonist Identity and Laboratory Documentation, What Is Retatrutide?, and Retatrutide vs Tirzepatide.
A sequence name or a weekly-exposure claim on a secondary article is not a specification. Aggregation, content, and the exact analogue should be visible on the quotation, the label, and the report.
Published clinical-research observations — and their limits
In the STEP 1 trial, Wilding and colleagues randomly assigned 1,961 adults with overweight or obesity, without diabetes, to once-weekly semaglutide or placebo, plus a lifestyle intervention, for 68 weeks. They reported a mean body-weight change from baseline of −14.9% in the semaglutide group and −2.4% in the placebo group, an estimated treatment difference of −12.4 percentage points (Wilding et al., 2021).
Frías and colleagues later compared once-weekly tirzepatide with once-weekly semaglutide in a 40-week, open-label, phase 3 trial in type 2 diabetes. They reported that tirzepatide was noninferior and superior to semaglutide for the mean change in glycated hemoglobin from baseline to week 40 (Frías et al., 2021). That paper is a published comparison of two named analogues in a defined patient population. It is not a protocol, and it does not make the two materials interchangeable in a laboratory file.
Those findings are attributed clinical-research observations. They are not administration or dosing guidance, and they do not describe a current catalog lot.
Identity, purity, content, and aggregation
A useful quality review still separates analogue identity, purity, content, and signs of aggregation. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.
Semaglutide appears in Velnacor’s research-material catalog (internal product record, slug semaglutide). There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact SKU and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.
Selected published literature
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726. PubMed 26308095.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PubMed 33567185. Cited as published clinical-research observations, not as a use instruction.
- Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PubMed 34170647. Cited as published clinical-research observations, not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.